搜尋結果
A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2 ), the virus that causes coronavirus disease 2019 ( COVID‑19 ). Prior to the COVID‑19 pandemic, an established body of knowledge existed about the structure and function of coronaviruses causing ...
- none
- Intramuscular
- mRNA, viral, inactivated, protein
- SARS-CoV-2
Skycovione is a COVID-19 vaccine candidate developed by SK Bioscience and the Institute for Protein Design of the University of Washington, [2] [3] [4] [5] [6] [7] [8] It is South Korea's first homegrown COVID-19 vaccine [9] and utilizes GSK 's AS03 adjuvant technology. The phase III clinical trial involves 4,037 participants.
- GBP510, Skycovion
- SARS-CoV-2
COVID-19 is the deadliest pandemic in US history; [358] it was the third-leading cause of death in the US in 2020, behind heart disease and cancer. [359] From 2019 to 2020, US life expectancy dropped by 3 years for Hispanic Americans, 2.9 years for African Americans, and 1.2 years for white Americans. [360]
- 6,956,160 (reported), 17.5–31.4 million (estimated)
- Worldwide
- Coronavirus disease 2019 (COVID-19)
- Severe acute respiratory syndromecoronavirus 2 (SARS‑CoV‑2)
- 新冠肺炎-疫苗資訊最前線
v. t. e. The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV, [2] the Sinopharm COVID-19 vaccine, [3] or BIBP vaccine, [3] [4] [5] is one of two whole inactivated virus COVID-19 vaccines developed by Sinopharm 's Beijing Institute of Biological Products (sometimes written as Beijing Bio-Institute of Biological Products, [6] resulting ...
- Zhong'aikewei (Chinese: 众爱可维), Hayat-Vax
- SARS-CoV-2
18.2–33.5 million [6] (estimated) Coronavirus disease 2019 ( COVID-19) is a contagious disease caused by the coronavirus SARS-CoV-2. The first known case was identified in Wuhan, China, in December 2019. [7] Most scientists believe the SARS-CoV-2 virus entered into human populations through natural zoonosis, similar to the SARS-CoV-1 and MERS ...
- 6,960,770 (reported), 17.6–31.4 million (estimated)
- SARS-CoV-2
- 2–14 days (typically 5), after infection
- Symptomatic and supportive
Covaxin (development name, BBV152) is a whole inactivated virus-based COVID-19 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research - National Institute of Virology. On 3 November 2021, the World Health Organization (WHO) validated the vaccine for emergency use, as the first Indian-developed covid vaccine to be approved.
Timeline. Locations. International response. Medical response. Variants. Economic impact and recession. Impacts. COVID-19 portal. v. t. e. Sinopharm NVSI COVID-19 vaccine, also known as mutI-tri-RBD or NVSI-06-08, is a COVID-19 vaccine developed by National Vaccine & Serum Institute (NVSI, 中生研究院), a subsidiary of CNBG of Sinopharm. [1] [2]
